ON SEPTEMBER 26, a group of public health experts wrote an open letter to Dr Albert Bourla, CEO of US pharma giant Pfizer, which is developing a Covid-19 vaccine candidate with German firm BioNTech. The company’s mRNA vaccine is one of the world’s leading candidates, and Bourla’s claims of a “clinical answer” to its phase 3 trials by October end has triggered safety concerns among a section of global experts. In the letter, they urge the company to wait until the end of November before seeking emergency authorisation for the vaccine to ensure that rigorous safety standards are followed and public trust and confidence in the vaccine is guaranteed.
According to the WHO, 40 vaccine candidates are being clinically evaluated, of which 10 have entered phase 3 trials, which involve testing the vaccine on thousands of people. In that context, the next couple of months will be crucial for regulators, vaccine manufacturers and distributors across the world, and put the world’s best delivery systems to test. With emerging possibilities of emergency use authorisation (EUA) for multiple candidates, safety and immunogenicity data is also being closely evaluated.
Union Health Minister Dr Harsh Vardhan has said that India is considering EUA, too. An EUA allows the vaccine to be used before it is fully licenced, after conducting a risk-benefit analysis based on available data. Normally, the third trial [phase 3] takes about six to nine months. But if the government decides, this period can be cut short through an EUA, Vardhan said. “Any emergency authorisation is always done by adopting reinforced safeguards so that people do not worry about safety,” he said. “A high-level group has been formed to monitor the pace of the vaccine development under the direct guidance of Prime Minister Narendra Modi. There will be no shortcut on safety. EUA will be given only if it meets the standards.”
This story is from the October 11, 2020 edition of THE WEEK.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the October 11, 2020 edition of THE WEEK.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.
Already a subscriber? Sign In
BIOPIC AND BEYOND
Randeep Hooda may have proved his acting credentials with biopics, but typecast him at your own peril
Flutter of flimsy wings
Butterfly Research Centre in Bhimtal boasts 3,500 butterfly and moth specimens
SIMILAR STATES, DIFFERENT BATTLES
The Congress seems to have the edge in Telangana while in Andhra Pradesh, Chandrababu Naidu and Jagan Mohan Reddy are locked in a bitter battle
A RIDE TO REMEMBER
On board Andhra Pradesh Chief Minister Y.S. Jagan Mohan Reddy’s bus as he was attacked
Winning 14 of 17 seats is my target
Anumula Revanth Reddy is on a mission to demonstrate a democratic and egalitarian facet of power and leadership.
LOTUS TAKES ROOT
Buoyed by its slowly growing acceptance among the voters in Tamil Nadu, the BJP is mounting its fiercest offensive ever
BLANK CHECK
Several factors favour an increase in the BJP’s vote share in Kerala, but whether the party can win a seat remains uncertain
CONGRESS HAS A HISTORY OF MAKING ADJUSTMENTS WITH COMMUNAL FORCES
In April 2021, as Chief Minister Pinarayi Vijayan was leading the CPI(M)’s assembly poll campaign to win a second consecutive term, a spirited debate erupted in Kerala over an epithet that party workers had bestowed on him.
POLL PLOT
Congress hopes its five guarantees’ will blunt BJP’s aggressive push
MODI'S GUARANTEES REMAIN IN SPEECHES, MY GUARANTEES ARE FULFILLED
The transformation is unmissable. The old-school mass leader Siddaramaiah has suddenly switched into the new avatar of a master strategist.